证券代码：688363 证券简称：华熙生物 公告编号：2025-043 华熙生物科技股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持有的基本情况 截至本公告披露日，国寿成达（上海）健康产业股权投资中心（有限合伙）（以 下简称"国寿成达"）直接持有华熙生物科技股份有限公司（以下简称"本公 司""华熙生物"）股份数量为 28,936,504 股，占华熙生物总股本的 6.01%。上 述股份全部为本公司首次公开发行前股份，并已于 2022 年 11 月 7 日起上市流通。 减持计划的主要内容 国寿成达计划根据市场情况通过集中竞价、大宗交易的方式减持其所持有的华熙 生物股份合计不超过 9,633,564 股，拟减持股份数量占华熙生物总股本的比例合 计不超过 2.00%，其中以集中竞价方式减持比例不超过 1.00%，减持数量不超过 4,816,782 股，以大宗交易方式减持比例不超过 1.00%，减持数量不超过 4,816,782 股，减持期间为减持股份计划公告披 ...

Core Viewpoint - Guoshou Chengda plans to reduce its holdings in Huaxi Biological through centralized bidding and block trading, with a maximum reduction of 9.6336 million shares, accounting for no more than 2% of the company's total share capital [1] Group 1 - Guoshou Chengda's reduction plan involves a total of up to 9.6336 million shares [1] - The proposed reduction represents a maximum of 2% of Huaxi Biological's total share capital [1]

人民财讯11月4日电，华熙生物(688363)11月4日公告，公司持股6.01%的股东国寿成达计划根据市场情 况通过集中竞价、大宗交易的方式减持其所持有的公司股份合计不超过963.36万股，拟减持股份数量占 公司总股本的比例合计不超过2%。 ...

Core Viewpoint - Guoshou Chengda plans to reduce its holdings in Huaxi Biological by up to 9.6336 million shares, representing no more than 2% of the company's total share capital [1] Summary by Category - **Share Reduction Plan** - Guoshou Chengda intends to reduce its stake in Huaxi Biological through centralized bidding and block trading methods [1] - The total number of shares to be reduced is up to 9.6336 million [1] - The proposed reduction accounts for a maximum of 2% of the company's total share capital [1]

华熙生物公告，截至公告披露日，持股2893.65万股（占6.01%）的股东国寿成达拟自2025年11月26日至 2026年2月23日，通过集中竞价减持不超481.68万股（不超1.00%）及大宗交易减持不超481.68万股（不 超1.00%），合计不超963.36万股，减持比例不超2.00%。 ...

Group 1 - The medical beauty sector experienced a decline of 2.68% on November 4, with Jinbo Biological leading the drop [1] - The Shanghai Composite Index closed at 3960.19, down 0.41%, while the Shenzhen Component Index closed at 13175.22, down 1.71% [1] - Major stocks in the medical beauty sector showed varied performance, with *ST Meigu closing at 3.74 (+0.27%), Huaxi Biological at 52.05 (-2.01%), Aimeike at 151.92 (-3.46%), and Jinbo Biological at 243.02 (-4.84%) [1] Group 2 - The medical beauty sector saw a net outflow of 101 million yuan from institutional investors, while retail investors had a net inflow of 79.55 million yuan [1] - The trading volume and turnover for key stocks included *ST Meigu with 140,600 shares traded and a turnover of 53.3 million yuan, Huaxi Biological with 29,200 shares and 153 million yuan, Aimeike with 43,500 shares and 669 million yuan, and Jinbo Biological with 15,400 shares and 378 million yuan [1]

格隆汇11月4日｜华熙生物(688363.SH)公告称，股东国寿成达（上海）健康产业股权投资中心（有限合 伙）计划通过集中竞价或大宗交易方式减持公司股份合计不超过963.36万股，占公司总股本比例不超过 2.00%，其中集中竞价减持不超过481.68万股，大宗交易减持不超过481.68万股。减持原因为自身资金 需求，减持期间为2025年11月26日至2026年2月23日。上述股份来源于公司首次公开发行前取得的股 份。 ...

Core Insights - The performance of the new consumption sector shows significant divergence, with companies like Pop Mart achieving impressive growth, while the capital market reacts with valuation adjustments [1] - The pet economy continues to attract capital attention, with companies like Zhongchong and Guai Bao Pet reporting steady growth, yet facing valuation declines [1] - The beauty economy, represented by companies like Aimeike and Huaxi Biological, is experiencing notable declines in performance [1] IP Economy Performance - Pop Mart reported a substantial revenue increase of 245%-250% year-on-year for Q3 2025, continuing its high growth trend from the first half of the year [2] - In the Chinese market, revenue grew by 185%-190%, with online channels surging by 300%-305% and offline channels by 130%-135% [2] - Overseas revenue skyrocketed by 365%-370%, with the Americas showing an extraordinary growth of 1265%-1270% [2] - Light Media also saw significant growth, with Q3 revenue reaching 3.616 billion yuan, a 150.81% increase, and net profit soaring by 406.78% [2][3] Pet Economy Trends - Zhongchong reported Q3 revenue of 3.860 billion yuan, up 21.05%, and net profit of 333 million yuan, up 18.21% [4] - Guai Bao Pet achieved Q3 revenue of 4.737 billion yuan, a 29.03% increase, with net profit growing by 9.05% [4] - Despite high market demand, the pet economy faces challenges from homogenization and increased competition [5] Beauty Economy Challenges - Aimeike's Q3 revenue fell by 21.49% to 1.865 billion yuan, with net profit down 31.05% [6] - Huaxi Biological reported a revenue decline of 18.36% to 3.163 billion yuan, with net profit decreasing by 30.29% [6] - Beitaini's revenue dropped by 13.78% to 3.464 billion yuan, with net profit down 34.45% [6] - The medical beauty industry is undergoing a strategic transformation, with a focus on high-end markets and new materials gaining attention [6][7]

Market Overview - The medical beauty sector experienced a decline of 1.4% on November 3, with Ai Meike leading the drop [1] - The Shanghai Composite Index closed at 3976.52, up 0.55%, while the Shenzhen Component Index closed at 13404.06, up 0.19% [1] Individual Stock Performance - *ST Meigu (000615) closed at 3.73, with an increase of 4.19% and a trading volume of 150,000 shares, totaling a transaction value of 5.5589 million yuan [1] - Jinbo Biological (920982) closed at 255.37, up 1.63%, with a trading volume of 15,700 shares and a transaction value of 403 million yuan [1] - Huaxi Biological (688363) closed at 53.12, down 1.61%, with a trading volume of 29,400 shares and a transaction value of 156 million yuan [1] - Ai Meike (300896) closed at 157.37, down 1.70%, with a trading volume of 33,400 shares and a transaction value of 5.271 billion yuan [1] Capital Flow Analysis - The medical beauty sector saw a net inflow of 2.7789 million yuan from main funds, while retail investors experienced a net outflow of 3.33256 million yuan [1] - Main funds for *ST Meigu showed a net inflow of 6.9892 million yuan, while retail investors had a net outflow of 652.99 thousand yuan [2] - Ai Meike had a net inflow of 1.4812 million yuan from main funds, but a net outflow of 1.89798 million yuan from retail investors [2] - Huaxi Biological experienced a net outflow of 5.6915 million yuan from main funds and a net outflow of 781.58 thousand yuan from retail investors [2]

中国经济网北京11月3日讯 安徽省药品监督管理局官网近期发布第一分局化妆品生产监督检查信息通告（2025年第5期）。 （责任编辑：徐自立） | 序号 | 检查时间 | 企业名称 | 生产地址 | 椅查范围 | 检查依据 | 检查结论 | 处理措施 | 备注 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 安徽省合肥经济技 | | 《化妆品监督管理条例》《化 妆品生产质量管理规范 » 《化 | 基本符合(生 | | | | 1 | 2025年9月4日 | 联合利益(中 | 术开发区锦绣大道 | 般液态单元、青霜乳液 | 妆品生产质量管理规范检查要 | 产质量管理体 | 限期營改 | 元 | | | | 国)有限公司 | 88号 | 单元、牙膏单元 | 点及判定原则》《化妆品检查 | 系存在缺陷) | | | | | | | | | 管理办法》等。 | | | | | 2 | | 联合利华(中 | 安徽省合肥经济技 | | 《化妆品监督管理条例》《化 妆品生产质量管理规范 » 《化 | | | 无 | | | 2025年9月4日 ...